William Blair Investment Management LLC Sells 54,253 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

William Blair Investment Management LLC trimmed its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 9.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 505,581 shares of the medical equipment provider's stock after selling 54,253 shares during the quarter. William Blair Investment Management LLC owned 0.73% of Lantheus worth $40,593,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of the company. UMB Bank n.a. raised its stake in shares of Lantheus by 161.4% during the 1st quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 247 shares during the period. GAMMA Investing LLC raised its stake in shares of Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock worth $26,000 after purchasing an additional 208 shares during the period. Principal Securities Inc. bought a new stake in shares of Lantheus during the 4th quarter worth $28,000. Fidelis Capital Partners LLC bought a new stake in shares of Lantheus during the 1st quarter worth $34,000. Finally, FinTrust Capital Advisors LLC raised its stake in shares of Lantheus by 53.6% during the 1st quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider's stock worth $41,000 after purchasing an additional 232 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Price Performance

Shares of LNTH traded up $1.52 during midday trading on Friday, hitting $105.55. 1,119,849 shares of the company traded hands, compared to its average volume of 1,028,340. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $126.89. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. The firm has a market cap of $7.33 billion, a P/E ratio of 16.11 and a beta of 0.50. The stock has a 50-day moving average of $104.91 and a 200-day moving average of $82.74.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). The company had revenue of $394.10 million during the quarter, compared to the consensus estimate of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The firm's revenue for the quarter was up 22.5% on a year-over-year basis. During the same quarter last year, the company posted $1.40 earnings per share. As a group, sell-side analysts predict that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Insider Buying and Selling

In related news, President Paul Blanchfield sold 2,000 shares of the company's stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total value of $192,780.00. Following the transaction, the president now directly owns 98,980 shares in the company, valued at $9,540,682.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Lantheus news, President Paul Blanchfield sold 2,000 shares of the stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total transaction of $192,780.00. Following the transaction, the president now directly owns 98,980 shares in the company, valued at $9,540,682.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Andrea Sabens sold 341 shares of the stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $123.15, for a total transaction of $41,994.15. Following the transaction, the chief accounting officer now owns 62,216 shares in the company, valued at $7,661,900.40. The disclosure for this sale can be found here. Over the last three months, insiders have sold 40,852 shares of company stock worth $3,922,001. Insiders own 1.50% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on LNTH. Truist Financial lowered their price objective on Lantheus from $141.00 to $135.00 and set a "buy" rating on the stock in a research note on Thursday, August 1st. B. Riley boosted their price objective on Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a research note on Thursday, July 25th. Redburn Atlantic began coverage on Lantheus in a research note on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price objective on the stock. Leerink Partners boosted their price objective on Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a research note on Thursday, July 11th. Finally, JMP Securities lowered their price objective on Lantheus from $130.00 to $125.00 and set a "market outperform" rating on the stock in a research note on Thursday, August 1st. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, Lantheus has a consensus rating of "Moderate Buy" and an average target price of $126.00.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.